Background
==========

Worldwide, the group of head and neck cancers are the eighth most common cancers and comprise between 5--10% of all cancers \[[@b1-medscimonit-25-8389]\]. There are an estimated 834,860 new cases worldwide, with approximately 431,131 annual deaths from head and neck cancer \[[@b1-medscimonit-25-8389]\]. More than 90% of head and neck cancers are squamous cell carcinoma, or head and neck squamous cell carcinoma (HNSCC), which has the eighth highest mortality rate of all cancers \[[@b2-medscimonit-25-8389],[@b3-medscimonit-25-8389]\]. Exposure to tobacco, excessive alcohol consumption, infection with Epstein-Barr virus (EBV) or human papillomavirus (HPV), and environmental exposure to carcinogens are the main causes of head and neck cancer. However, the risk of developing head and neck cancer varies even in populations with the same exposure to carcinogens, which might be explained by genetic susceptibility \[[@b4-medscimonit-25-8389],[@b5-medscimonit-25-8389]\]

Single nucleotide polymorphisms (SNPs) account for the majority of genetic mutations and are an important genetic cause for differences in cancer predisposition, sensitivity to radiotherapy and chemotherapy, and survival in cancer patients. These potential functions of SNPs in influencing cancer susceptibility, chemotherapy resistance, and therapeutic efficacy have been validated in several studies \[[@b6-medscimonit-25-8389],[@b7-medscimonit-25-8389]\]. A previously reported study analyzed more than 200 publications that reported the gene polymorphisms that influenced the risk of developing HNSCC \[[@b8-medscimonit-25-8389]\]. The genetic polymorphisms of HNSCC can be classified into several groups according to the biological functions of genes they regulate \[[@b8-medscimonit-25-8389]\]. Polymorphisms have been reported to involve genes involved in biotransformation and detoxification enzymes (ADH) \[[@b9-medscimonit-25-8389],[@b10-medscimonit-25-8389]\], the DNA repair pathway (XRCC1) \[[@b11-medscimonit-25-8389]\], the apoptosis pathway (PUMA) \[[@b11-medscimonit-25-8389]\], HPV-related HNSCC pathways \[[@b12-medscimonit-25-8389]\], mitochondrial DNA (np16362 \[T/C\] mtDNA) \[[@b13-medscimonit-25-8389]\], the bilirubin-related pathway (UGT1A1) \[[@b14-medscimonit-25-8389]\] and E2F transcription factors \[[@b15-medscimonit-25-8389]\].

Infection with HPV and EBV are risk factors for HNSCC. Transforming growth factor-β1 (TGF-β1) has an important role in inflammation and the immune responses that control the clearance of HPV and its escape from immune surveillance. The TGF-β1 T869C variant genotype has been reported to be significantly associated with HPV16-positive oropharyngeal cancer, but no significant association has been reported for the C509T or G915C polymorphisms of the TGF-β1 gene \[[@b12-medscimonit-25-8389]\]. Activation of the TGF-β1 gene is increased in patients with EBV-positive nasopharyngeal carcinoma (NPC) when compared with healthy EBV-seropositive individuals \[[@b16-medscimonit-25-8389]\]. Previous studies have shown that TGF-β1 levels increase during EBV infection, and TGF-β1 levels in patients with NPC significantly decrease at the end of the treatment \[[@b17-medscimonit-25-8389]\]. Inflammation has been considered as an important factor in the pathogenesis of human cancers \[[@b18-medscimonit-25-8389]\], including oral cancers \[[@b19-medscimonit-25-8389]\]. Expression levels of inflammatory factors and genes that encode inflammatory cytokines may reflect tumor progression \[[@b20-medscimonit-25-8389]\].

TGF-β1 is an inflammatory cytokine that inhibits cell proliferation and induces apoptosis in the early stages of neoplasia. The TGF-β1 gene is upregulated, and serum levels of TGF-β1 are increased in colon cancer \[[@b21-medscimonit-25-8389],[@b22-medscimonit-25-8389]\], prostate cancer \[[@b23-medscimonit-25-8389]\], and lung cancer \[[@b24-medscimonit-25-8389]\]. Genetic variations in the promoter region of the TGF-β1 gene may affect transcription and protein synthesis. The functions of TGF-β1 are inhibited during the late stages of cancer due to the inactivation of tumor suppressor gene P53 and alterations in the TGF-β1 signaling pathway, resulting in tumor cell invasion and metastasis \[[@b25-medscimonit-25-8389]--[@b27-medscimonit-25-8389]\]. Previous studies have reported an association between polymorphisms of the TGF-β1 gene and carcinogenesis in NPC \[[@b28-medscimonit-25-8389]\], lung cancer \[[@b29-medscimonit-25-8389]\], esophageal cancer \[[@b30-medscimonit-25-8389]\], prostate cancer \[[@b31-medscimonit-25-8389]\], colon cancer \[[@b32-medscimonit-25-8389]\], and gastric cancer \[[@b33-medscimonit-25-8389]\]. TGF-β1 gene polymorphisms have been reported to be associated with the occurrence and progression of HNSCC \[[@b34-medscimonit-25-8389]\]. Therefore, this study aimed to systematically review the literature and undertake a meta-analysis of case-control studies on the 869T/C, 509C/T, and 915G/C polymorphisms of the TGF-β1 gene and their associations with head and neck cancer.

Material and Methods
====================

Search strategies
-----------------

The databases searched included PubMed, Embase, Wanfang Data, and CNKI, up to 31st October 2018. The literature search terms included TGF-β1 gene polymorphisms, TGF, transforming growth factor, head and neck cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, and oropharyngeal cancer. The publications that were identified had their references manually checked.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were case-control studies that investigated the relationship between the TGF-β1 gene polymorphisms, 869T/C, 509C/T, and 915G/C, and predisposition to head and neck cancer. Published studies were identified that were in the English or Chinese language, and that provided the odds ratio (OR) and 95% confidence interval (CI). The exclusion criteria were studies that lacked a control group, duplicate publications, and studies with incomplete or insufficient data.

Data retrieval
--------------

Data were extracted from the identified publications by two independent researchers. The data recorded included the authors, year of publication, country of origin of the data, race or ethnicity of the patients, type of cancer, and the numbers of each polymorphism in the patient and case-control groups.

Statistical analysis
--------------------

The heterogeneity test (*I*^2^ test) was performed on the included studies. If the studies were homogenous, the data were combined and analyzed with a fixed-effects model. Otherwise, a random-effects model was used. The ORs and 95% CIs for the combined data analysis were calculated and processed for the sensitivity analysis. Egger's test was used to evaluate publication bias. Stata version 12.0 software (StataCorp, College Station, TX, USA) was used to analyze the data. The significance level of the tests was α=0.05.

Results
=======

Results of the literature retrieval and the basic characteristics of the studies
--------------------------------------------------------------------------------

A total of 124 studies were retrieved by searching for the keywords. Following the exclusion of studies that did not meet the inclusion criteria, ten case-control studies underwent meta-analysis \[[@b28-medscimonit-25-8389],[@b35-medscimonit-25-8389]--[@b43-medscimonit-25-8389]\]. The publication screening process is shown in [Figure 1](#f1-medscimonit-25-8389){ref-type="fig"}. The basic patient characteristics and the transforming growth factor-β1 TGF-β1 genotype distributions for the 869T/C rs1800470, 509C/T rs1800469, and 915G/C rs1800471 polymorphisms in the studies are shown in [Table 1](#t1-medscimonit-25-8389){ref-type="table"}.

There were eight studies that reported an association with the 869T/C polymorphism of the TGF-β1 gene, including 1,607 patient cases and 1,981 control cases. The patient cases included 1,363 cases of nasopharyngeal carcinoma (NPC), 244 cases of oropharyngeal cancer, 1,675 control cases for NPC, and 306 control cases for oropharyngeal cancer. Fives studies reported the association with the TGF-β1 gene 509C/T polymorphism, including four studies of NPC and one study of oropharyngeal cancer, involving 1,355 patient cases and 1,579 control cases. Among these data, there were 1,207 cases of NPC and 1,424 controls. The study sample size ranged from 42 to 158 in the three studies that reported an association with the TGF-β1 gene 915G/C polymorphism, involving 340 cases of patients with cancer and 368 controls. Cases of oropharyngeal cancer were reported in three studies.

Correlation between the 869T/C polymorphism of the TGF-β1 gene and susceptibility to head and neck cancer
---------------------------------------------------------------------------------------------------------

We analyzed each genotype generated by the 869T/C polymorphism of the TGF-β1 gene ([Tables 2](#t2-medscimonit-25-8389){ref-type="table"}, [3](#t3-medscimonit-25-8389){ref-type="table"}, [Figure 2](#f2-medscimonit-25-8389){ref-type="fig"}), and no differences were found. The allele comparison (C *vs.* T) showed: OR=1.141; 95% CI, 0.927--1.406; P=0.213. The results for the dominant gene analysis (TC+CC *vs.* TT) were: OR=1.179; 95% CI, 0.925--1.521; P=0.203. The results for the recessive gene analysis (CC *vs.* TT+TC) were: OR=1.209; 95% CI, 0.857--1.705; P=0.28. The results for the homologous gene analysis (CC *vs.* TT) were: OR=1.298; 95% CI, 0.859--1.962; P=0.216. However, analysis of all combined data showed a significant correlation between the 869T/C polymorphism of the TGF-β1 gene and susceptibility to head and neck cancer (OR=1.181; 95% CI, 1.035--1.348; P=0.014).

Subgroup analysis
-----------------

We conducted a subgroup analysis to include the different subtypes of head and neck cancer, different races, and different sample sizes. Only NPC and oropharyngeal cancer were identified in the studies selected. No significant differences were found between any two different genotypes for these two disease subtypes (P=0.131 and P=0.103, respectively).

The results for the allele and dominant gene analysis in the Asian population (C *vs.* T) were: OR=1.321; 95% CI, 0.974--1.93; P=0.074. For (TC+CC *vs.* TT) the findings were: OR=1.418; 95% CI, 0.921--2.184; P=0.112. The results for the recessive gene and homologous genotypes (CC *vs.* TT+TC) were: OR=1.564; 95% CI, 0.983--2.490; P=0.059. For CC *vs.* TT the findings were: OR 1.844; 95% CI, 0.920--3.497; P=0.061.

No significant differences were found in the subgroup analysis of each genotype in Asian populations, but the general analysis showed a significant difference (OR=1.431; 95% CI, 1.191--1.720; P=0.000) ([Figure 3](#f3-medscimonit-25-8389){ref-type="fig"}). No differences were also found between analyses for any of the genotypes or by the general analysis in non-Asian populations (P=0.320). A subgroup analysis based on sample size showed that for the subgroup with sample size \>100, the results for the allele and dominant genotype analyses (C *vs.* T) were: OR=1.203; 95% CI, 0.959--1.510; P=0.110). For (TC+CC *vs.* TT) the findings were: OR=1.202; 95% CI, 0.908--1.591; P=0.199. The results for the recessive genotype and homologous genotype analyses (CC *vs.* TT+TC) were: OR=1.266; 95% CI, 0.933--1.718; P=0.129. The findings for CC *vs.* TT were: OR=1.369; 95% CI, 0.918--2.043; P=0.124. Similar to the results based on patient race, no differences were found between the different genotypes, but the general analysis obtained a significant difference overall (OR=1.230; 95% CI, 1.078--1.404; P=0.002) ([Figure 4](#f4-medscimonit-25-8389){ref-type="fig"}).

The relationship between TGF-β1 gene polymorphisms and NPC
----------------------------------------------------------

Only one-fifth of cases of head and neck cancer were oropharyngeal cancer in the studies that we selected. To avoid selection bias, we analyzed the relationship between TGF-β1 gene polymorphisms and susceptibility to NPC ([Figure 5](#f5-medscimonit-25-8389){ref-type="fig"}). The results showed that TGF-β1 gene polymorphisms were not correlated with NPC. The previous general analysis results showed that polymorphisms at this site were correlated with patient race and sample size. Therefore, we conducted a racial subgroup analysis on the cases of NPC ([Table 4](#t4-medscimonit-25-8389){ref-type="table"}).

The results for each genotype in the Asian populations included the allele analysis (C *vs.* T) (OR=1.139; 95% CI, 0.857--1.512; P=0.370) and the dominant gene analysis (TC+CC *vs.* TT) (OR=1.118; 95% CI, 0.792--1.577; P=0.527). The results for the recessive gene analysis (CC *vs.* TT+TC) were (OR 1.212; 95% CI, 0.810--1.813; P=0.350) and for the homologous gene analysis (CC *vs.* TT) were (OR 1.276; 95% CI, 0.742--2.180; P=0.371).

The results for each genotype in the non-Asian populations included the allele analysis (C *vs.* T) (OR=0.997; 95% CI, 0.840--1.184; P=0.977) and the dominant gene analysis (TC+CC *vs.* TT) (OR=0.977, 95% CI: 0.760--1.255; P=0.853). The results for the recessive gene analysis (CC *vs.* TT+TC) were (OR=1.057; 95% CI, 0.667--1.650; P=0.808) and for the homologous gene analysis (CC *vs.* TT) were (OR 1.012, 95% CI: 0.687--1.490; P=0.952). No significant differences were observed between the genotypes in the Asian and non-Asian populations. As the sample size of NPC cases in our selected studies was \>100, we did not conduct a sample size analysis.

Correlation between the 509C/T polymorphism of the TGF-β1 gene and susceptibility to head and neck cancer
---------------------------------------------------------------------------------------------------------

Five studies that reported the association between the 509C/T polymorphism of the TGF-β1 gene and head and neck cancers were identified in this study. Only one study reported the findings in patients with oral cancer. All the other studies involved cases of NPC. Therefore, we only analyzed the relationship between 509C/T polymorphism of the TGF-β1 gene and NPC. Because the I^2^ value was \>50%, we chose a random-effects model for the statistical analysis. The results for each genotype were as follows ([Tables 2](#t2-medscimonit-25-8389){ref-type="table"}, [3](#t3-medscimonit-25-8389){ref-type="table"}, [Figure 6](#f6-medscimonit-25-8389){ref-type="fig"}): T *vs.* C (OR=1.047; 95% CI, 0.748--1.466; P=0.789); TC+TT *vs.* CC (OR=1.118; 95% CI, 0.758--1.648; P=0.575); TT *vs.* CC+CT (OR=1.176; 95% CI, 0.727--1.902; P=0.508); and TT *vs.* CC (OR=1.123; 95% CI, 0.601--2.096; P=0.716). No difference was found for the general analysis (OR=1.133; 95% CI, 0.937--1.370; P=0.198). Therefore, the meta-analysis did not support a correlation between the 509C/T polymorphism of the TGF-β1 gene and NPC.

Correlation between the 915G/C polymorphism of the TGF-β1 gene and susceptibility to head and neck cancer
---------------------------------------------------------------------------------------------------------

All three studies that included the 915G/C polymorphism of the TGF-β1 gene were conducted in Asian populations and reported the findings in patients with oral cancer. The statistical results demonstrated a significant correlation between the 915G/C polymorphism of the TGF-β1 gene and oral cancer (OR=2.815; 95% CI, 1.581--5.012; P=0.000). The allele and dominant genotype (C *vs.* G) analysis results showed a significant difference (OR=3.800; 95% CI, 1.125--12.843; P=0.032), and GC+CC *vs.* GG (OR=5.113; 95% CI, 1.224--21.367; P=0.025). The results for the recessive genotype and homologous gene (CC *vs.* GG+GC) showed no significant difference (OR=1.343; 95% CI, 0.710--2.538; P=0.364) and (CC *vs.* GG) (OR=1.598; 95% CI, 0.812--2.146; P=0.175) ([Figure 7](#f7-medscimonit-25-8389){ref-type="fig"}).

Publication bias and sensitivity analysis
-----------------------------------------

Egger's test was used to determine publication bias. The P-value for the allele and genotype (C *vs.* T) analysis was P=0.343; TC+CC *vs.* TT was P=0.258; CC *vs.* TT+TC was P=0.095; and CC *vs.* TT was P=0.05. The results for Egger's test for each genotype of the 509C/T polymorphism and the 915G/C polymorphism for T *vs.* C was P=0.445; TC+TT *vs.* CC was P=0.408; TT *vs.* CC+CT was P=0.771; TT *vs.* CC was P=0.678; and C *vs.* G was P=0.226; GC+CC *vs.* GG was P=0.327; CC *vs.* GG+GC was P=0.263; and CC *vs.* GG wasP=0.417, respectively. These results indicated a relatively little publication bias in each group. The sensitivity test showed that the results for the three polymorphisms were stable ([Figure 8](#f8-medscimonit-25-8389){ref-type="fig"}), with a relatively small publication bias in each group ([Figure 9](#f9-medscimonit-25-8389){ref-type="fig"}).

Discussion
==========

The susceptibility to difference cancers, and sensitivity to cancer treatments, varies between individuals in the same environment and may be explained not only by different physical conditions but also by genetic susceptibility. Changes in gene expression are key events in the occurrence and progression of cancer. Previously published studies have shown that cancer can be associated with chronic inflammation, tissue injury, and the activation of local host responses that induce cell proliferation \[[@b44-medscimonit-25-8389]\].

Transforming growth factor-β1 (TGF-β1) is an inflammatory cytokine that has important roles in the carcinogenesis and the development of solid malignant tumors. Lu et al. \[[@b45-medscimonit-25-8389]\] showed that both *in vivo* and *in vitro* levels of TGF-β1 were increased in tumor cells from head and neck cancer, indicating that overexpression of TGF-β1 may provide an oncogenic microenvironment. Also, TGF-β1 may contribute to the aggressive behavior of cancers through a local and systemic immunosuppression effect \[[@b26-medscimonit-25-8389]\]. Several single nucleotide polymorphisms (SNPs) have been evaluated for their possible roles in inflammatory diseases and cancer predisposition. TGF-β1 SNPs are believed to influence downstream gene expression and further affect the susceptibility to head and neck cancer. Previous studies have investigated TGF-β1 or TGF-β1 genetic polymorphisms as a predictive cancer marker \[[@b46-medscimonit-25-8389],[@b47-medscimonit-25-8389]\]. In the classic TGF-β/Smad signaling pathway, TGF-β1 is phosphorylated after binding to its receptor, and phosphorylates Smad2 and Smad3, and then binds to Smad4. This cytoplasmic complex is transferred to the cell nucleus and interacts with other transcription factors, with abnormalities in this complex resulting in abnormal cell proliferation \[[@b48-medscimonit-25-8389],[@b49-medscimonit-25-8389]\]. It has previously been reported that TGF-β1 is overexpressed in many types of cancers, and the levels are correlated with tumor invasion \[[@b21-medscimonit-25-8389]--[@b24-medscimonit-25-8389]\]. Expression of TGF-β1 and Smad7 in the tumor tissues are increased in head and neck cancer tissues, while Smad4 is downregulated \[[@b50-medscimonit-25-8389]\]. TGF-β1 gene polymorphisms are also correlated with treatment response and the prognosis \[[@b51-medscimonit-25-8389]\]. Therefore, it is possible to hypothesize that TGF-β1 gene polymorphisms affect serum levels of TGF-β1 and Smad, leading to the inactivation of the TGF-β1/Smad signaling pathway, which might result in changes that influence the prognosis of head and neck cancer.

In this meta-analysis, TGF-β1 gene polymorphisms and susceptibility to head and neck cancer were investigated. The 869T/C polymorphism was associated with the development of head and neck cancer. Further subgroup analysis showed that this association was more significant in the Asian population. The subtypes of head and neck cancers included in this study were nasopharyngeal cancer (NPC) and oral cancer. No significant differences were found in the analysis of each genotype. However, a significant difference was found in the general analysis, suggesting that TGF-β1 gene polymorphisms were correlated with different subtypes of head and neck cancer. However, subgroups analysis of the different tumor stages of head and neck cancer was not performed.

Four publications reported the 869T/C and 509C/T polymorphisms of the TGF-β1 gene in NPC. However, no association was observed in the analysis if these two polymorphic sites of the TGF-β1 gene and NPC. Wei et al. \[[@b28-medscimonit-25-8389]\] previously reported that both 869T/C and 509C/T polymorphisms of the TGF-β1 gene were associated with a predisposition to NPC. Hu et al. \[[@b36-medscimonit-25-8389]\] discovered that the allele mutation at position 509T reduced the risk of NPC, while a T to C mutation at position 869 was not associated with carcinogenesis in NPC. However, the findings from a study reported by Qu et al. \[[@b35-medscimonit-25-8389]\] of the population of Northern China and the findings from a study by Khaali et al. \[[@b37-medscimonit-25-8389]\] of patients in the population of North America population showed that neither the 869T/C polymorphism of the TGF-β1 gene nor the 509C/T polymorphism were associated with the genesis of NPC. Differences in biological behavior and in the mechanisms underlying the genesis of NPC when compared with other tumors explain these findings. Therefore, further studies are needed to determine the genetic effects of these two sites. Also, racial differences exist between genotypes. The population of Southern China is at increased risk of NPC, whereas its incidence is relatively low in Northern China and North America.

In this study, the meta-analysis showed that the 915G/C polymorphism of the TGF-β1 gene was associated with susceptibility to oral cancer. The 915G/C polymorphism resides in the 25^th^ codon of the TGF-β1 gene. In three studies, the 915G/C polymorphism and oral cancer were associations in the Asian population. However, Gaur et al. \[[@b42-medscimonit-25-8389]\] reported that the TGF-β1 C allele is not a risk factor for oral cancer. Hsu et al. \[[@b40-medscimonit-25-8389]\] showed that the G/C genotype increased the risk of oral cancer. A study by Hsu et al. \[[@b41-medscimonit-25-8389]\] further validated the pivotal role of the TGF-β1 gene C allele in precancerous lesions and oral cancer. The meta-analyses in the present study showed that the C dominant allele was a risk factor for oral cancer, which may be explained by the role of the G allele in increasing serum level of TGF-β1 levels, inhibiting epithelial cell proliferation and transformation. The polymorphism causes the G allele to be transformed to the C allele, leading to a substitution of arginine by proline at the protein level. This substitution may change the overall hydrophobic nature of the core sequence. Therefore, the α-helical structure is impaired and transported to the endoplasmic reticulum, leading to proliferation and transformation of epithelial cells, which increases the risk for oral cancer \[[@b45-medscimonit-25-8389]\]. Chen et al. \[[@b17-medscimonit-25-8389]\] reported low TGF-β1 expression in NPC, which was upregulated after clinical treatment. Changes in TGF-β1 levels associated with the inflammatory reaction are closely associated with the side effects of the treatment.

This study had several limitations. First, the publication sample size for the meta-analysis was small. There were only three published studies on the 915G/C polymorphism of the TGF-β1 gene that were included, which are likely to be insufficient to determine its association with oral cancer. Second, only Chinese and English publications were screened, and studies published in other languages and unpublished data were not included. Future studies should include a larger sample size to validate the findings from this meta-analysis.

Conclusions
===========

A meta-analysis of the published literature supported an association between the 869T/C polymorphism of the TGF-β1 gene and head and neck cancer, particularly in the Asian population. The 915G/C allele genotype and the dominant TGF-β1 genotype were associated with oral cancer, but the recessive and homozygous genotypes were not. The meta-analysis data did not support an association between the 509C/T polymorphism and head and neck cancers, including nasopharyngeal carcinoma (NPC).
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###### 

Basic characteristics and the genotype distributions of TGF-β1 in the selected studies.

  Gene     Author         Year          Country       Cancer type     Number    Case   Control   P(hwe)                     
  -------- -------------- ------------- ------------- --------------- --------- ------ --------- -------- ----- ----- ----- -------
  869T/C   Yanli Qu       2016          China         NPC             193/231   51     75        36       65    114   52    0.88
  869T/C   Ye-Sheng Wei   2007          China         NPC             108/120   16     49        43       30    61    29    0.85
  869T/C   Sunhong Hu     2012          China         NPC             522/712   129    266       127      187   354   171   0.89
  869T/C   Wafa Khaali    2016          Morocco       NPC             384/361   132    165       64       119   149   67    0.10
  869T/C   N.K Carneiro   2013          Brazil        Oral            62/62     22     29        11       20    19    23    0.79
  869T/C   Poonam Gaur    2011          India         Oral            140/120   51     58        31       70    39    11    0.21
  869T/C   Khaled S.      2011          SaudiArabia   NPC             156/251   51     67        38       83    120   48    0.69
  869T/C   Han-Jan Hsu    2014          Taiwan        Oralprecancer   42/124    1      37        4        8     113   3     0.000
           **Case**       **Control**   **P(hwe)**                                                                          
  **CC**   **TC**         **TT**        **CC**        **TC**          **TT**                                                
  509C/T   Yanli Qu       2016          China         NPC             193/231   62     116       53       121   83    39    0.84
  509C/T   Ye-Sheng Wei   2007          China         NPC             108/120   17     46        45       29    60    31    0.99
  509C/T   Sunhong Hu     2012          China         NPC             522/712   208    224       80       203   337   172   0.16
  509C/T   Wafa Khaali    2016          Morocco       NPC             384/361   127    153       44       120   148   56    0.37
  509C/T   Esther Erdei   2013          America       Oral            148/155   73     54        21       76    57    22    0.04
           **Case**       **Control**   **P(hwe)**                                                                          
  **GG**   **GC**         **CC**        **GG**        **GC**          **CC**                                                
  915G/C   Poonam Gaur    2011          India         Oral            140/120   55     58        27       59    44    17    0.080
  915G/C   Han-Jan Hsu    2014          Taiwan        Oralprecancer   42/124    25     17        0        115   8     1     0.06
  915G/C   Han-Jan Hsu    2014          Taiwan        Oral            158/124   84     74        0        115   8     1     0.06

###### 

Results of the meta-analysis for the association between TGF-β1 gene polymorphisms and head and neck cancers.

  869T/C                   N                 Sample size       C *vs.* T                TC+CC *vs.* TT                                                                                  
  ------------------------ ----------------- ----------------- ------------------------ -------------------- ----------------- ---------- ------------------------- ----------- ------- ------
  Total                    8                 1607/1981         1.141 \[0.927--1.406\]   0.213                0.000             74.3       1.179 \[0.915--1.521\]    0.203       0.028   55.5
  Type of cancer                                                                                                                                                                        
   NPC                     5                 1363/1675         1.071 \[0.912--1.257\]   0.404                0.079             52.2       1.039 \[0.875--1.235\]    0.660       0.359   8.3
   Oral                    3                 244/306           1.222 \[0.590--2.528\]   0.590                0.000             86.9       1.648 \[0.720--3.773\]    0.237       0.070   62.4
  Ethnicities                                                                                                                                                                           
   Asian                   5                 761/1001          1.321 \[0.974--1.793\]   0.074                0.001             79.4       1.418 \[0.921--2.184\]    0.112       0.011   69.4
   Caucasian               3                 602/674           0.931 \[0.729--1.190\]   0.568                0.149             47.5       0.965 \[0.761--1.223\]    0.767       0.767   0.0
  Sample size                                                                                                                                                                           
   \>100                   6                 1259/1489         1.203 \[0.959--1.510\]   0.110                0.000             77.7       1.202 \[0.908--1.591\]    0.199       0.013   65.6
   ≤100                    2                 104/186           0.892 \[0.458--1.735\]   0.736                0.059             71.9       1.026 \[0.452--2.330\]    0.950       0.296   8.5
  Publication bias tests                                                                                                                                                                
  Egger's P                                                    0.343                    0.258                                                                                           
  **509C/T**               **N**             **Sample size**   **T *vs.* C**            **CT+TT *vs.* CC**                                                                              
  **Case/control**         **OR (95% CL)**   ***P*b**          ***P*c**                 **I^2^%**            **OR (95% CL)**   ***P*b**   ***P*c**                  **I^2^%**           
  Total                    5                 1335/1559         1.111 \[0.749--1.647\]   0.601                0.000             93.3       1.024 \[0.669--1.567\]    0.914       0.000   86.9
  Type of cancer                                                                                                                                                                        
   NPC                     4                 1215/1520         1.047 \[0.748--1.466\]   0.789                0.000             86.7       1.118 \[0.758--1.648\]    0.575       0.006   76.2
  Publication bias tests                                                                                                                                                                
  Egger's P                                                    0.445                                                                      0.408                                         
  **915G/C**               **N**             **Sample size**   **C *vs.* G**            **GC+CC *vs.* GG**                                                                              
  **Case/control**         **OR (95% CL)**   ***P*b**          ***P*c**                 **I^2^%**            **OR (95% CL)**   ***P*b**   ***P*c**                  **I^2^%**           
  Total                    3                 340/368           3.800 \[1.125--12.843    0.032                0.000             91.7       5.113 \[1.224--21.367\]   0.025       0.000   91.9
  Publication bias tests                                                                                                                                                                
  Egger's P                                                    0.226                    0.327                                                                                           

TGF-β1 -- transforming growth factor-β1; CI -- confidence interval; OR -- odds ratio. Note: *P*b Value of the Z test for odds ration test. *P*c Value of the Q test for hetergeneity test. *P* Value of the Egger's test for publication bias.

###### 

Results of meta-analysis on the association between the TGF-β1 gene polymorphisms and head and neck cancers.

  869T/C                   N          CC *vs.* TT+TC           CC *vs.* TT       All                                                                                                                                          
  ------------------------ ---------- ------------------------ ----------------- ----------------- ---------- ------------------------- ----------- ----------------- ---------- ------------------------ ----------- ------- ------
  Total                    8          1.209 \[0.857--1.705\]   0.28              0.001             70.4       1.298 \[0.859--1.962\]    0.216       0.001             71.4       1.181 \[1.035--1.348\]   0.014       0.000   66.1
  Type of cancer                                                                                                                                                                                                              
   NPC                     5          1.131 \[0.875--1.463\]   0.346             0.105             47.7       1.138 \[0.836--1.548\]    0.411       0.099             48.8       1.077 \[0.978--1.186\]   0.131       0.075   33.2
   Oral                    3          1.537 \[0.324--7.290\]   0.589             0.000             87.1       2.134 \[0.345--13.218\]   0.415       0.001             86.1       1.469 \[0.925--2.333\]   0.103       0.000   78.9
  Ethnicities                                                                                                                                                                                                                 
   Asian                   5          1.564 \[0.983--2.490\]   0.059             0.009             70.2       1.844 \[0.972--3.497\]    0.061       0.002             76.6       1.431 \[1.191--1.720\]   0.000       0.000   70.3
   Caucasian               3          0.824 \[0.456--1.489\]   0.521             0.025             72.9       0.874 \[0.539--1.420\]    0.587       0.137             49.7       0.929 \[0.804--1.074\]   0.320       0.017   28.9
  Sample size                                                                                                                                                                                                                 
   \>100                   6          1.266 \[0.933--1.718\]   0.129             0.017             63.6       1.369 \[0.918--2.043\]    0.124       0.004             71.2       1.230 \[1.078--1.404\]   0.002       0.000   66.4
   ≤100                    2          1.140 \[0.104--12.17\]   0.915             0.006             86.7       1.714 \[0.075--38.984\]   0.735       0.021             81.3       0.920 \[0.545--1.552\]   0.754       0.009   62.6
  Publication bias tests                                                                                                                                                                                                      
  Egger's P                           0.095                    0.05                                                                                                                                                           
  **509C/T**               **N**      **TT *vs.* CC+CT**       **TT *vs.* CC**   **All**                                                                                                                                      
  **OR (95% CL)**          ***P*b**   ***P*c**                 **I^2^%**         **OR (95% CL)**   ***P*b**   ***P*c**                  **I^2^%**   **OR (95% CL)**   ***P*b**   ***P*c**                 **I^2^%**           
  Total                    5          1.108 \[0.603--2.036\]   0.521             0.000             91.5       1.138 \[0.542--2.390\]    0.733       0.000             92.4       1.090 \[0.865--1.374\]   0.464       0.000   90.4
  Type of cancer                                                                                                                                                                                                              
  NPC                      4          1.176 \[0.727--1.902\]   0.508             0.001             80.6       1.123 \[0.601--2.096\]    0.716       0.000             84         1.133 \[0.937--1.370\]   0.198       0.000   79.1
  Publication bias tests                                                                                                                                                                                                      
  Egger's P                           0.771                    0.678                                                                                                                                                          
  **915G/C**               **N**      **CC *vs.* GG+GC**       **CC *vs.* GG**   **All**                                                                                                                                      
  **OR (95% CL)**          ***P*b**   ***P*c**                 **I^2^%**         **OR (95% CL)**   ***P*b**   ***P*c**                  **I^2^%**   **OR (95% CL)**   ***P*b**   ***P*c**                 **I^2^%**           
  Total                    3          1.343 \[0.710--2.538\]   0.364             0.574             0.0        1.598 \[0.812--3.146\]    0.175       0.734             0.0        2.815 \[1.581--5.012\]   0.000       0.000   81.1
  Publication bias tests                                                                                                                                                                                                      
  Egger's P                           0.263                    0.417                                                                                                                                                          

TGF-β1 -- transforming growth factor-β1; CI -- confidence interval; OR -- odds ratio. Note: *P*b Value of the Z test for odds ration test. *P*c Value of the Q test for hetergeneity test. *P* Value of the Egger's test for publication bias

###### 

Meta-analysis on the association between the TGF-β1 869 T/C gene polymorphisms and nasopharyngeal carcinoma in different ethnicities.

  Gene type        Asian                  Non-Asian   All                                                                                                 
  ---------------- ---------------------- ----------- ------- ------ ---------------------- ------- ------- ------ ---------------------- ------- ------- ------
  C *vs.* T        1.139 (0.857--1.512)   0.370       0.032   70.9   0.997 (0.840--1.184)   0.977   0.316   0.6    1.071 (0.912--1.257)   0.404   0.079   52.2
  TC+CC *vs.* TT   1.118 (0.792--1.577)   0.527       0.141   48.9   0.977 (0.760--1.255)   0.853   0.817   0.0    1.039 (0.875--1.235)   0.660   0.359   8.3
  CC *vs.* TT+TC   1.212 (0.810--1.813)   0.350       0.070   62.4   1.057 (0.677--1.650)   0.808   0.144   53.1   1.131 (0.875--1.463)   0.346   0.105   47.7
  CC *vs.* TT      1.276 (0.747--2.180)   0.371       0.048   67.2   1.012 (0.687--1.490)   0.952   0.255   22.8   1.138 (0.836--1.548)   0.411   0.099   48.8

TGF-β1 -- transforming growth factor-β1; CI -- confidence interval; OR -- odds ratio. *P*b Value of the Z test for odds ration test. *P*c Value of the Q test for hetergeneity test. *P* Value of the Egger's test for publication bias.
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